Onset and Duration of Vardenafil's Therapeutic Effect

This study is being run at up to 50 study centers in Europe and South Africa to evaluate the use of vardenafil in adult men with erectile dysfunction (often called impotence), and their female partner's sexual quality of life.

Contraindication	Explanation	Note
Nitrate medication use	Can cause severe hypotension	Avoid use within 24 hours of nitrates
Severe cardiovascular disease	Increased risk of adverse cardiac events	Consult with cardiologist
Hypersensitivity to Vardenafil	Known allergy to the drug or ingredients	Discontinue if allergic reactions occur
Liver impairment	Reduced metabolism leading to higher drug levels	Dose adjustment may be necessary

Many men experience occasional erectile problems during their lives. However, when this becomes a continued problem, it can affect both the man and his female partner.

Primary Outcome

The causes of erectile dysfunction are varied and may be due to physiological or emotional reasons. This study is designed to 1) study the effectiveness and safety of vardenafil, and 2) show whether treating a man its erectile dysfunction with vardenafil will improve his female partner its sexual quality of life.

• Vardenafil may be used as part of a broader erectile health program.
• Lifestyle changes, like exercise, can enhance medication effects.
• It is important to avoid excessive alcohol while on Vardenafil.
• The medication's safety profile is well-established.
• Patients with kidney problems should consult a healthcare provider.
• The drug is not effective without sexual stimulation.
• Vardenafil is contraindicated with some heart medications.
• A healthcare provider can determine the appropriate dose.
• Never take expired Vardenafil, as effectiveness declines.

The second part (week 12) of the study (Educational program) a subgroup of subjects/couples, approximately 50% of the randomized subjects, will receive an educational program concerning ED in the from of a DVD.

• Priapism (prolonged erection) is a rare but serious risk.
• Seek emergency care if erection lasts over 4 hours.
• Sudden vision or hearing loss requires immediate attention.

Key Participants Requirements Sex Male Age 18 - 64 Years Inclusion Criteria expand_more - Males 18 to 64 years - Males with ED for more than six months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance) - Stable heterosexual relationship for more than 6 months - The subject must make at least four attempts at sexual intercourse - Documented, dated, written Informed Consent Partner - Females 18 years, and older - Stable, heterosexual relationship for more than 6 months with male ED subject - Documented, dated, written Informed Consent - Motivated to support treatment for male partner's ED - Absence of significant sexual dysfunction as assessed by the total score on the FSFI16 > 23.55 Exclusion Criteria expand_more - Any unstable medical condition or substance abuse disorder that, in the opinion of the Investigator, is likely to affect the patient's ability to complete the study or precludes the patient's participation in the study - Subjects who are taking nitrates or nitric oxide donors - Subjects who are taking the following inhibitors of cytochrome P 450 CYP 3A4: very potent HIV protease inhibitors (ritonavir, indinavir), the anti-mycotic agents traconazole and ketoconazole (topical blue tablets forms are allowed) or erythromycin - Known hypersensitivity to vardenafil - Presence of significant penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) - History of retinitis pigmentosa - Unstable angina pectoris - Severe chronic or acute liver disease - Premature ejaculator (defined as IELT < 2 minutes) - Subjects who were taking alpha blockers - Lost of vision of one eye because of NAION Trial summary Enrollment Goal 352 Trial Dates July 2006 - August 2007 Phase Phase 4 Could I Receive a placebo Yes Products Levitra (Vardenafil, BAY38-9456) Accepts Healthy Volunteer No Where to participate Status Institution Location Completed Praxis Hr. Policlinico Umberto I Roma, 00155, Italy Not yet recruiting A.O. Prof.

Product	Dosage	Quantity + Bonus	Price
Kamagra Soft Tabs	100mg	84 + 4 Pills	233.05€ 221.95€	Buy
Kamagra Polo	100 mg	180 + 8 Pills	446.52€ 425.26€	Buy
Cialis Generic	10mg	20 Pills	48.23€ 45.93€	Buy
Levitra Generic	60mg	180 + 10 Pills	501.43€ 477.55€	Buy
Viagra Oral Jelly	100mg	63 + 7 Sachets	190.54€ 181.47€	Buy
Kamagra Gold	100 mg	360 + 6 Pills	839.95€ 799.95€	Buy
Viagra Generic	150mg	20 Pills	55.02€ 52.40€	Buy
Super Kamagra	160 mg	12 Pills	101.10€ 96.29€	Buy
Viagra Generic	100mg	90 + 6 Pills	129.02€ 122.88€	Buy
Viagra Original	100mg	12 Pills	72.54€ 69.09€	Buy
Cialis Generic	20mg	10 Pills	31.49€ 29.99€	Buy
Kamagra Gold	100 mg	180 + 6 Pills	436.79€ 415.99€	Buy
Cialis Generic	2.5mg	360 + 10 Pills	260.03€ 247.65€	Buy

Dr.

Key Participants Requirements

This study is being run at up to 50 study centers in Europe and South Africa to evaluate the use of vardenafil in adult men with erectile dysfunction (often called impotence), and their female partner's sexual quality of life. Many men experience occasional erectile problems during their lives. However, when this becomes a continued problem, it can affect both the man and his female partner. The causes of erectile dysfunction are varied and may be due to physiological or emotional reasons. This study is designed to 1) study the effectiveness and safety of vardenafil, and 2) show whether treating a man its erectile dysfunction with vardenafil will improve his female partner its sexual quality of life.

Pharmacokinetics and Pharmacodynamics

The second part (week 12) of the study (Educational program) a subgroup of subjects/couples, approximately 50% of the randomized subjects, will receive an educational program concerning ED in the from of a DVD. Key Participants Requirements Sex Male Age 18 - 64 Years Inclusion Criteria expand_more - Males 18 to 64 years - Males with ED for more than six months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance) - Stable heterosexual relationship for more than 6 months - The subject must make at least four attempts at sexual intercourse - Documented, dated, written Informed Consent Partner - Females 18 years, and older - Stable, heterosexual relationship for more than 6 months with male ED subject - Documented, dated, written Informed Consent - Motivated to support treatment for male partner's ED - Absence of significant sexual dysfunction as assessed by the total score on the FSFI16 > 23.55 Exclusion Criteria expand_more - Any unstable medical condition or substance abuse disorder that, in the opinion of the Investigator, is likely to affect the patient's ability to complete the study or precludes the patient's participation in the study - Subjects who are taking nitrates or nitric oxide donors - Subjects who are taking the following inhibitors of cytochrome P 450 CYP 3A4: very potent HIV protease inhibitors (ritonavir, indinavir), the anti-mycotic agents traconazole and ketoconazole (topical blue tablets forms are allowed) or erythromycin - Known hypersensitivity to vardenafil - Presence of significant penile anatomical abnormalities (e.g. penile fibrosis or Peyronie's disease) - History of retinitis pigmentosa - Unstable angina pectoris - Severe chronic or acute liver disease - Premature ejaculator (defined as IELT < 2 minutes) - Subjects who were taking alpha blockers - Lost of vision of one eye because of NAION Trial summary Enrollment Goal 352 Trial Dates July 2006 - August 2007 Phase Phase 4 Could I Receive a placebo Yes Products Levitra (Vardenafil, BAY38-9456) Accepts Healthy Volunteer No Where to participate Status Institution Location Completed Praxis Hr. Policlinico Umberto I Roma, 00155, Italy Not yet recruiting A.O. Prof.

Mechanism of Action

Dr. H. Porst Hamburg, 20354, Germany Completed Praxis Hr. Dr. E. H.

At a glance

U. Krohn Hamburg, 22177, Germany Completed Praxis Hr. Dr. F. Matthes Leisnig, 04703, Germany Completed Praxis Fr.

Onset and Duration of Action

Dr. W. Pohl Dresden, 01129, Germany Completed Praxis Drs. Careggi Firenze, 50139, Italy Completed Hospital Policlínico de Vigo - Clínica Povisa Vigo, 36211, Spain Completed Hospital Universitario de Canarias La Laguna, 38320, Spain Completed Hospital General Universitario de Alicante Alicante, 03010, Spain Completed Hospital Fundació Puigvert Barcelona, 08025, Spain Completed CAP Sarrià Barcelona, 08034, Spain Completed CHU de Liège LIEGE, 4000, Belgium Completed Dr Bongaerts - Dr Denier GENK, 3600, Belgium Completed Medisch Spectrum Twente, Locatie Ariensplein ENSCHEDE, 7511 JX, Netherlands Completed Deventer Ziekenhuis DEVENTER, 7415 EH, Netherlands Completed Private Practice Dr MK Dhanjee Newcastle, 2940, South Africa Completed Randles Road Medical Centre Durban, 4091, South Africa Completed Newkwa Medical Centre Durban, 4037, South Africa Completed Parklands Medical Centre - Durban Durban, 4091, South Africa Primary Outcome Maintenance of erection in men with ED, Improvement of their female partners sexual quality of life date_range Time Frame: 12 weeks enhanced_encryption Safety Issue: no Secondary Outcome SEP3 at weeks 4, 12, 18, and 24 of treatment compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Additional Subject Diary questions at weeks 4, 12, 18, and 24, LOCF, and over entire treatment period compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Global confidence question (GCQ) at weeks 12, and 24 of treatment compared to placebo. IIEF, TSS, mSLQQ-QOL, Partnership questionnaire (PFB20) date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Trial design A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners sexual quality of life.

Patient Counseling Points

PARTNER II Trial Type Interventional Intervention Type Drug Trial Purpose Treatment Allocation Randomized Blinding Double Blind Assignment Parallel Assignment Trial Arms 2 Additional Information Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. Click here to find information about studies related to Bayer Healthcare products conducted in Europe Click here to find results for studies related to Bayer Healthcare products. Sexual Encounter Profile Question 2 and 3 and International Index of Erectile Function - Erectile Function domaindate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Duration of erection leading to positive Sexual Encounter Profile Question 3date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Safety and tolerabilitydate_rangeTime Frame:12 weeksenhanced_encryptionyesSafety Issue: Other patient diary based variablesdate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: The change from baseline in Fansworth Munsell (FM) 100 test total error score (TES) in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The change from baseline in Electroretinogram (ERG) as measured by amplitude and implicit time of b wave in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Change in the FM-100 total error score from baseline at approximately 6 hours and 24 hours post dosedate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Safety and tolerability of 20 mg vardenafil after at least 15 oral doses of 20 mg vardenafil or placebo (dosed over approximately 8 weeks)date_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: ERG and FM-100 total error score from baseline at approximately 2 hours following one dose of sildenafil 200 mgdate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The Bayer Clinical Trials Registry and Results Database website contains information on clinical trials sponsored by Bayer, and is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. The information sex erection tablet contained within the website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Porst Hamburg, 20354, Germany Completed Praxis Hr. Dr. E. U. Krohn Hamburg, 22177, Germany Completed Praxis Hr. Dr.

Patient Type	Starting Dose	Max Dose	Notes
Adults with ED	10 mg, taken 1 hour before activity	20 mg	Adjust based on efficacy and tolerability
Elderly patients	5 mg or lower	10 mg	Increased caution due to metabolism changes
Patients on CYP3A4 inhibitors	5 mg	10 mg	Reduce dose to prevent side effects

F. Matthes Leisnig, 04703, Germany Completed Praxis Fr. Dr. W. Pohl Dresden, 01129, Germany Completed Praxis Drs. Careggi Firenze, 50139, Italy Completed Hospital Policlínico de Vigo - Clínica Povisa Vigo, 36211, Spain Completed Hospital Universitario de Canarias La Laguna, 38320, Spain Completed Hospital General Universitario de Alicante Alicante, 03010, Spain Completed Hospital Fundació Puigvert Barcelona, 08025, Spain Completed CAP Sarrià Barcelona, 08034, Spain Completed CHU de Liège LIEGE, 4000, Belgium Completed Dr Bongaerts - Dr Denier GENK, 3600, Belgium Completed Medisch Spectrum Twente, Locatie Ariensplein ENSCHEDE, 7511 JX, Netherlands Completed Deventer Ziekenhuis DEVENTER, 7415 EH, Netherlands Completed Private Practice Dr MK Dhanjee Newcastle, 2940, South Africa Completed Randles Road Medical Centre Durban, 4091, South Africa Completed Newkwa Medical Centre Durban, 4037, South Africa Completed Parklands Medical Centre - Durban Durban, 4091, South Africa Primary Outcome Maintenance of erection in men with ED, Improvement of their female partners sexual quality of life date_range Time Frame: 12 weeks enhanced_encryption Safety Issue: no Secondary Outcome SEP3 at weeks 4, 12, 18, and 24 of treatment compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Additional Subject Diary questions at weeks 4, 12, 18, and 24, LOCF, and over entire treatment period compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Global confidence question (GCQ) at weeks 12, and 24 of treatment compared to placebo. IIEF, TSS, mSLQQ-QOL, Partnership questionnaire (PFB20) date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Trial design A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners sexual quality of life. PARTNER II Trial Type Interventional Intervention Type Drug Trial Purpose Treatment Allocation Randomized Blinding Double Blind Assignment Parallel Assignment Trial Arms 2 Additional Information Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Ghi chú

Patients should always seek medical advice before making any decisions on their treatment. Healthcare professionals should always refer to the specific labeling information approved for the patient's country or region. The data on the website should not be considered as prescribing advice. The data on the website may differ from published or presented data and are a reflection of the limited information provided there. The results from a single trial need to be considered in the context of the full clinical research for a drug.

Highest Development Phases

All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of the information available through the site. Bayer may amend the information at any time without notice. aDepartment of Urology and Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, 77 Mitropoleos str., 546 22 Thessaloniki, Greece DOI: 10.1016/j.eururo.2004.01.014 External LinkAlso available on ScienceDirect External Link Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction The potential value of erectile dysfunction inquiry and management Hellstrom, W. ∙ Gittelman, M. ∙ Karlin, G.

Ebola Bundibugyo Virus Outbreak in the DRC and Uganda: What Pharmacists Need to Know

..., on behalf of the Vardenafil Study Group Sustained efficacy and tolerability of vardenafil (Levitra®), a highly potent, selective phosphodiesterase-5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Wie wirksam sind die PDE-5 Hemmstoffe When an erection alone is not enough: biopsychosocial obstacles to lovemaking Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users Drop out reason in responders to sildenafil Click here to find information about studies related to Bayer Healthcare products conducted in Europe Click here to find results for studies related to Bayer Healthcare products. Sexual Encounter Profile Question 2 and 3 and International Index of Erectile Function - Erectile Function domaindate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Duration of erection leading to positive Sexual Encounter Profile Question 3date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Safety and tolerabilitydate_rangeTime Frame:12 weeksenhanced_encryptionyesSafety Issue: Other patient diary based variablesdate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: The change from baseline in Fansworth Munsell (FM) 100 test total error score (TES) in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The change from baseline in Electroretinogram (ERG) as measured by amplitude and implicit time of b wave in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Change in the FM-100 total error score from baseline at approximately 6 hours and 24 hours post dosedate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Safety and tolerability of 20 mg vardenafil after at least 15 oral doses of 20 mg vardenafil or placebo (dosed over approximately 8 weeks)date_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: ERG and FM-100 total error score from baseline at approximately 2 hours following one dose of sildenafil 200 mgdate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The Bayer Clinical Trials Registry and Results Database website contains information on clinical trials sponsored by Bayer, and is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research.

• Vardenafil's chemical structure contributes to its potency.
• It is manufactured by Bayer, a reputable pharmaceutical company.
• Patients should avoid combining Vardenafil with high-fat meals.
• The drug's metabolism involves the liver, requiring caution.
• It can cause temporary vision changes, like color discrimination.
• Vardenafil is marketed in several countries worldwide.
• It is not intended for use in women or animals.
• Patients should seek medical advice if they experience allergic reactions.
• Regular follow-up helps optimize ED treatment outcomes.

The information sex erection tablet contained within the website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare professionals should always refer to the specific labeling information approved for the patient's country or region. The data on the website should not be considered as prescribing advice. The data on the website may differ from published or presented data and are a reflection of the limited information provided there. The results from a single trial need to be considered in the context of the full clinical research for a drug. All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of the information available through the site. Bayer may amend the information at any time without notice.

• Patients with severe kidney or liver impairment need dose adjustment.
• Not recommended for those with severe heart conditions.
• Caution in patients with retinitis pigmentosa.

aDepartment of Urology and Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, 77 Mitropoleos str., 546 22 Thessaloniki, Greece DOI: 10.1016/j.eururo.2004.01.014 External LinkAlso available on ScienceDirect External Link Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction The potential value of erectile dysfunction inquiry and management Hellstrom, W. ∙ Gittelman, M. ∙ Karlin, G. ..., on behalf of the Vardenafil Study Group Sustained efficacy and tolerability of vardenafil (Levitra®), a highly potent, selective phosphodiesterase-5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Wie wirksam sind die PDE-5 Hemmstoffe When an erection alone is not enough: biopsychosocial obstacles to lovemaking Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users Drop out reason in responders to sildenafil